Document Detail


Use of clofarabine for acute childhood leukemia.
MedLine Citation:
PMID:  20631817     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
A second-generation of purine nucleoside analogs, starting with clofarabine, has been developed in the course of the search for new therapeutic agents for acute childhood leukemia, especially for refractory or relapsed disease. Clofarabine is a hybrid of fludarabine and cladribine, and has shown to have antileukemic activity in acute lymphoblastic leukemia as well as in myeloid disorders. As the only new antileukemic chemotherapeutic agent to enter clinical use in the last 10 years, clofarabine was approved as an orphan drug with the primary indication of use in pediatric patients. Toxicity has been tolerable in a heavily pretreated patient population, and clofarabine has been demonstrated to be safe, both as a single agent and in combination therapies. Liver dysfunction has been the most frequently observed adverse event, but this is generally reversible. Numerous Phase I and II trials have recently been conducted, and are still ongoing in an effort to find the optimal role for clofarabine in various treatment strategies. Concomitant use of clofarabine, cytarabine, and etoposide was confirmed to be safe and effective in two independent trials. Based on the promising results when used as a salvage regimen, clofarabine is now being investigated for its potential to become part of frontline protocols.
Authors:
A Pession; R Masetti; K Kleinschmidt; A Martoni
Related Documents :
24560087 - Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder ...
23975267 - Controversies in the role of radiotherapy in the treatment of pediatric hodgkin lymphoma.
23949547 - Prognostic value of preoperative (18)f-fdg pet/ct for primary head and neck squamous ce...
24924547 - Prediction of glioma recurrence using dynamic 18f-fluoroethyltyrosine pet.
2297647 - Serous ovarian tumors of low malignant potential with peritoneal implants.
3701387 - Complete axillary lymph node dissection for stage i-ii carcinoma of the breast.
Publication Detail:
Type:  Journal Article     Date:  2010-06-24
Journal Detail:
Title:  Biologics : targets & therapy     Volume:  4     ISSN:  1177-5491     ISO Abbreviation:  Biologics     Publication Date:  2010  
Date Detail:
Created Date:  2010-07-15     Completed Date:  2011-07-14     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101321511     Medline TA:  Biologics     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  111-8     Citation Subset:  -    
Affiliation:
Pediatric Oncology and Hematology "Lalla Seràgnoli", University of Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COP...
Next Document:  Managing idiopathic short stature: role of somatropin (rDNA origin) for injection.